Eli Lilly, the makers of tirzepatide—which they sell as Mounjaro for diabetes and Zepbound for weight loss— announced recently that in its longest study yet on tirzepatide, the drug reduced the risk of people with prediabetes moving on to develop diabetes by 94% compared to those taking a placebo.

Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as new antibody drugs emerge.

Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study. Read my thoughts on this weight loss drug and the road ahead for TERN.